{"filing":{"accession_number":"0001193125-26-331512","cik":"0001882782","ticker":"ODTX","company_name":"Odyssey Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-04","primary_document":"odtx-20260804.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1882782/000119312526331512/odtx-20260804.htm"},"events":[{"id":23862,"run_id":21583,"accession_number":"0001193125-26-331512","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a quarterly earnings release for Q2 2026 (three months ended June 30, 2026) disclosing financial results including research and development expenses ($36.2M), general and administrative expenses ($10.5M), and net loss ($52.8M), along with cash position ($433.1M) and operational updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24211,"accession_number":"0001193125-26-331512","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (three months ended June 30, 2026) disclosing financial results including research and development expenses ($36.2M), general and administrative expenses ($10.5M), and net loss ($52.8M), along with cash position ($433.1M) and operational updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:09.349706+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24211,"accession_number":"0001193125-26-331512","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a quarterly earnings release for Q2 2026 (three months ended June 30, 2026) disclosing financial results including research and development expenses ($36.2M), general and administrative expenses ($10.5M), and net loss ($52.8M), along with cash position ($433.1M) and operational updates. The press release is furnished as Exhibit 99.1 under Item 2.02, which is the standard Item for results of operations and financial condition disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:23:09.349706+00:00","company_name":"Odyssey Therapeutics, Inc.","ticker":"ODTX","filing_date":"2026-08-04"}]}